Real Anthropic Deployment

How Recursion Pharmaceuticals Uses Claude AI

A documented Claude deployment in biotech & genomics: the challenge, the solution, the measurable results — and what your organisation can learn from it.

01 — Background

About Recursion Pharmaceuticals

Recursion Pharmaceuticals is a leading organisation in the biotech & genomics sector. Like most biotech & genomics organisations at scale, they faced growing operational complexity — more volume, higher expectations, and a workforce stretched thin by routine but critical tasks.

02 — Challenge

The Problem

Recursion's scientists generated terabytes of biological imaging data weekly but needed AI that could synthesise scientific literature, interpret experimental results, and connect findings to published research at a pace matching their discovery programmes.

03 — Solution

How They Used Claude

Integrated Claude into their scientific intelligence platform, enabling researchers to query the entirety of published biomedical literature in natural language, cross-reference experimental findings, and generate hypothesis documents for team review.

04 — Results

Measurable Outcomes

"Claude allows our scientists to think at the speed of biology, not the speed of literature searching."

— Recursion Pharmaceuticals · Source: Recursion Pharmaceuticals technology announcements + Nature Biotechnology features (2024)

Key Lessons for Biotech & Genomics Organisations

Lesson 1

Start with a clearly scoped pilot — one use case, one team, 30 days.

Lesson 2

Measure baseline metrics before deployment so ROI is unambiguous.

Lesson 3

Executive sponsorship drives adoption; middle management drives usage.

Lesson 4

Invest in training alongside technology — adoption is 80% people, 20% product.

Ready to achieve similar results in your Biotech & Genomics organisation?

Our 90-day implementation programme delivers measurable ROI or we extend at no charge.

Book Free Assessment →
The Claude Bulletin

Weekly Claude deployment intelligence

3,000+ enterprise leaders read it every week. Join them.